Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

12 nov. 2021 08h05 HE | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update

- Ongoing pivotal intranasal abuse study of lead program, ADAIR, advancing toward completion of patient enrollment and treatment in Q1 2022 - Advancement of second development program, ADMIR, with...
12 oct. 2021 08h35 HE | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Provides Update on Recent Pipeline and Corporate Advancements

- Lead program, ADAIR, advancing toward completion of patient enrollment and treatment in ongoing SEAL study - Selection of final formulation completed for second development program, ADMIR ...
13 avr. 2021 08h05 HE | Source: Vallon Pharmaceuticals Inc.

Vallon Pharmaceuticals Continues Advancement of Pivotal Study in Lead Development Program, ADAIR, Toward Potential Approval

- Ongoing ADAIR SEAL study on target for pivotal data readout in second half of 2021- Target NDA filing in Q2 2022 for a potential abuse-deterrent alternative to commercially available IR amphetamines...